Matinas Biopharma (MTNB) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

—

Revenue (quarter)

—

Revenue growth (year over year)

—

Gross profit (trailing twelve months)

—

Gross margin

—

Net income (trailing twelve months)

—

Net income (quarter)

−$1.3M

Net income growth (year over year)

+74.72%

Net margin

—

Return on equity

−154.28%

EPS (trailing twelve months)

−$8.29

Book value per share

$4.21

P/E (trailing twelve months)

—

Price to book

1.49

Debt to assets

47.25%

Payout ratio

—

Dividend yield

—

Company profile

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

• How do I buy stock in Matinas Biopharma (MTNB)?

  MTNB trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.